JERUSALEM, May 15, 2026
Scinai Immunotherapeutics announced that its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe in Amsterdam, focusing on how oral peptide and small molecule therapies are reshaping the future of biologics in immunology and dermatology. The discussion will be led by Amir Reichman alongside Meital Portugal. The session will examine whether oral therapies can compete with or complement injectable biologics across immune-mediated diseases, while addressing evolving treatment strategies, patient adherence, and long-term disease control.
The roundtable will cover several critical industry questions, including whether oral cytokine blockers can deliver biologic-level efficacy and durability, which disease areas are most vulnerable to disruption from oral therapies, and whether administration convenience could become a key differentiator in immunology drug development. The discussion will also address clinical development challenges such as pharmacokinetic variability, bioavailability limitations, treatment persistence, and sustained therapeutic response. Scinai stated that the immunology sector is moving beyond efficacy-focused innovation toward broader considerations including accessibility, convenience, and strategic modality selection.
Focus on Oral Therapies and Biologics
According to Scinai, advances in oral peptide therapies and small molecules could significantly influence future immunology treatment sequencing and commercial strategy. The company believes some immune pathways may continue to favor injectable biologics, while others may shift toward oral therapies due to patient preference, ease of administration, and long-term adherence benefits. Industry discussions are increasingly centered on balancing convenience with efficacy, safety, and durability in chronic inflammatory disease management.
The summit session will also explore how oral immunology therapies may affect physician confidence, payer reimbursement dynamics, and lifecycle management strategies for established biologic franchises. Scinai executives emphasized that future treatment approaches may involve a combination of biologics and oral therapeutics depending on disease type and patient response profiles. The company sees these evolving modalities as an important strategic consideration for next-generation immunology drug development.
Scinai Expands Immunology Innovation Strategy
Advertisement
Scinai is advancing a pipeline of immunology therapies targeting inflammatory and immune-mediated diseases using differentiated cytokine-targeting approaches and advanced biologic formats. The company’s broader development strategy includes both therapeutic innovation and manufacturing capabilities through its CDMO subsidiary, Scinai Biopharma Services, which provides drug development and manufacturing services to biotech and pharmaceutical companies.
The 7th Dermatology Drug Development Summit Europe brings together pharmaceutical companies, biotechnology firms, translational researchers, and clinicians focused on advancing dermatology therapeutics and immune-mediated disease innovation. Scinai’s participation highlights the growing industry focus on oral immunology therapeutics as companies seek more patient-friendly and commercially scalable alternatives to injectable biologics.
Source: Scinai Immunotherapeutics press release
